mitochondrial ribosomal protein S17 pseudogene 9Genealiases: []
Q-omics provides the consensus-scored MRPS17P9 profile across patient tissues and cancer cell-line models. MRPS17P9 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, MRPS17P9 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, MRPS17P9 RNA expression shows 4,719 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THYM, BRCA, and STAD as cancer lineages where MRPS17P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPS17P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPS17P9 survival associations across molecular data types. MRPS17P9 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPS17P9 RNA expression–survival associations across cancer types. High MRPS17P9 expression shows unfavorable associations in THYM, DLBC, ACC, HNSC and READ, but favorable associations in LIHC. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify THYM as the clearest survival context for MRPS17P9 RNA expression.
This table summarizes MRPS17P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MRPS17P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPS17P9 shows lower tumor expression in BRCA and higher tumor expression in LUSC and KIRP. The BRCA box plot shows higher MRPS17P9 RNA expression in normal versus tumor tissue (log2 FC = −0.039, t-test p = .035).
This table shows molecular features associated with MRPS17P9 in patient tissues and cancer cell lines. In patient samples, MRPS17P9 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
